Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 120 | 2024 | 17352 | 2.970 |
Why?
|
Anti-HIV Agents | 55 | 2024 | 4527 | 2.380 |
Why?
|
Reverse Transcriptase Inhibitors | 22 | 2022 | 621 | 1.590 |
Why?
|
Benzoxazines | 23 | 2015 | 316 | 1.570 |
Why?
|
HIV-1 | 49 | 2024 | 6863 | 1.460 |
Why?
|
Antiretroviral Therapy, Highly Active | 24 | 2019 | 1897 | 1.000 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2024 | 3245 | 0.980 |
Why?
|
Anti-Retroviral Agents | 15 | 2023 | 1784 | 0.950 |
Why?
|
Ritonavir | 9 | 2016 | 329 | 0.880 |
Why?
|
Quinolines | 8 | 2024 | 764 | 0.880 |
Why?
|
Cardiovascular Diseases | 23 | 2024 | 15501 | 0.800 |
Why?
|
Oxidoreductases, N-Demethylating | 4 | 2013 | 110 | 0.800 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 244 | 0.760 |
Why?
|
Viral Load | 27 | 2024 | 3332 | 0.760 |
Why?
|
HIV Protease Inhibitors | 6 | 2016 | 432 | 0.750 |
Why?
|
Plaque, Atherosclerotic | 9 | 2024 | 1533 | 0.750 |
Why?
|
Dideoxynucleosides | 9 | 2015 | 135 | 0.720 |
Why?
|
Drug Resistance, Viral | 15 | 2023 | 862 | 0.640 |
Why?
|
Alkynes | 23 | 2015 | 320 | 0.640 |
Why?
|
Cyclopropanes | 23 | 2015 | 432 | 0.610 |
Why?
|
RNA, Viral | 19 | 2024 | 2846 | 0.600 |
Why?
|
Methotrexate | 5 | 2024 | 1719 | 0.580 |
Why?
|
Randomized Controlled Trials as Topic | 16 | 2024 | 10212 | 0.540 |
Why?
|
Coronary Artery Disease | 10 | 2024 | 6403 | 0.530 |
Why?
|
CD4 Lymphocyte Count | 20 | 2024 | 2571 | 0.500 |
Why?
|
Glucuronosyltransferase | 2 | 2012 | 132 | 0.500 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2015 | 2199 | 0.500 |
Why?
|
Unsafe Sex | 1 | 2016 | 238 | 0.480 |
Why?
|
Cyclohexanes | 4 | 2016 | 152 | 0.480 |
Why?
|
Oxazines | 6 | 2006 | 350 | 0.430 |
Why?
|
HIV | 11 | 2023 | 1582 | 0.420 |
Why?
|
HIV Seropositivity | 3 | 2020 | 960 | 0.420 |
Why?
|
Nevirapine | 5 | 2013 | 273 | 0.370 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 114 | 0.350 |
Why?
|
Triazoles | 4 | 2016 | 903 | 0.330 |
Why?
|
Treatment Failure | 16 | 2021 | 2644 | 0.320 |
Why?
|
Drug Therapy, Combination | 16 | 2016 | 6312 | 0.310 |
Why?
|
Research Subjects | 2 | 2020 | 249 | 0.300 |
Why?
|
Brachial Artery | 2 | 2020 | 366 | 0.300 |
Why?
|
Oligopeptides | 2 | 2014 | 1187 | 0.300 |
Why?
|
Double-Blind Method | 22 | 2024 | 12341 | 0.290 |
Why?
|
Male | 97 | 2024 | 360842 | 0.280 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 831 | 0.280 |
Why?
|
Atherosclerosis | 5 | 2024 | 3408 | 0.280 |
Why?
|
Female | 101 | 2024 | 392686 | 0.270 |
Why?
|
Middle Aged | 70 | 2024 | 220920 | 0.260 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2019 | 857 | 0.250 |
Why?
|
Humans | 132 | 2024 | 761572 | 0.250 |
Why?
|
Adult | 75 | 2024 | 221203 | 0.240 |
Why?
|
Multicenter Studies as Topic | 5 | 2020 | 1702 | 0.230 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2016 | 2151 | 0.220 |
Why?
|
HIV Integrase Inhibitors | 2 | 2023 | 165 | 0.210 |
Why?
|
HIV Integrase | 1 | 2023 | 121 | 0.200 |
Why?
|
Medication Adherence | 6 | 2014 | 2176 | 0.200 |
Why?
|
Lipoproteins, LDL | 3 | 2024 | 642 | 0.190 |
Why?
|
Anti-Inflammatory Agents | 3 | 2022 | 1809 | 0.190 |
Why?
|
Pyridines | 2 | 2014 | 2875 | 0.190 |
Why?
|
HIV Long-Term Survivors | 2 | 2020 | 121 | 0.190 |
Why?
|
Proteinuria | 1 | 2024 | 607 | 0.190 |
Why?
|
Inflammation | 8 | 2024 | 10773 | 0.190 |
Why?
|
CD4-CD8 Ratio | 2 | 2020 | 114 | 0.180 |
Why?
|
Primary Prevention | 4 | 2023 | 1186 | 0.180 |
Why?
|
Albuminuria | 1 | 2024 | 657 | 0.180 |
Why?
|
Bone Density | 5 | 2017 | 3551 | 0.170 |
Why?
|
Viremia | 2 | 2014 | 707 | 0.170 |
Why?
|
Zidovudine | 7 | 2010 | 624 | 0.150 |
Why?
|
Models, Statistical | 3 | 2022 | 5079 | 0.150 |
Why?
|
Indinavir | 4 | 2010 | 73 | 0.150 |
Why?
|
Research Design | 2 | 2022 | 6180 | 0.150 |
Why?
|
Pharmacogenetics | 3 | 2011 | 675 | 0.150 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2016 | 1351 | 0.140 |
Why?
|
Plasma | 3 | 2015 | 586 | 0.140 |
Why?
|
Treatment Outcome | 25 | 2019 | 64684 | 0.140 |
Why?
|
Lamivudine | 6 | 2007 | 366 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4176 | 0.140 |
Why?
|
Osteoporosis | 2 | 2017 | 1606 | 0.140 |
Why?
|
Risk Factors | 21 | 2024 | 74213 | 0.140 |
Why?
|
Vasodilation | 1 | 2020 | 962 | 0.140 |
Why?
|
Endothelium | 1 | 2019 | 765 | 0.130 |
Why?
|
Adenine | 3 | 2014 | 987 | 0.130 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 462 | 0.130 |
Why?
|
HIV Seronegativity | 2 | 2020 | 211 | 0.130 |
Why?
|
Body Composition | 3 | 2016 | 2426 | 0.130 |
Why?
|
Nelfinavir | 3 | 2004 | 68 | 0.130 |
Why?
|
Amino Acids | 2 | 2020 | 1718 | 0.130 |
Why?
|
Hair | 1 | 2019 | 498 | 0.120 |
Why?
|
Calcium Carbonate | 1 | 2015 | 62 | 0.120 |
Why?
|
Coronary Disease | 1 | 2010 | 5914 | 0.120 |
Why?
|
Immunomodulation | 1 | 2019 | 549 | 0.120 |
Why?
|
Condoms | 1 | 2016 | 331 | 0.120 |
Why?
|
Calcifediol | 1 | 2015 | 161 | 0.120 |
Why?
|
Vitamin D | 2 | 2019 | 3303 | 0.120 |
Why?
|
Gender Identity | 1 | 2020 | 766 | 0.120 |
Why?
|
Sexual Partners | 2 | 2016 | 796 | 0.110 |
Why?
|
Child Mortality | 1 | 2016 | 205 | 0.110 |
Why?
|
Abdominal Fat | 1 | 2016 | 221 | 0.110 |
Why?
|
Computer Simulation | 1 | 2007 | 6241 | 0.110 |
Why?
|
Infant Mortality | 2 | 2016 | 759 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2015 | 15936 | 0.110 |
Why?
|
Quality of Life | 4 | 2007 | 13367 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 2 | 2013 | 465 | 0.110 |
Why?
|
Nucleosides | 2 | 2022 | 131 | 0.110 |
Why?
|
HIV Reverse Transcriptase | 3 | 2010 | 212 | 0.100 |
Why?
|
Coronary Angiography | 5 | 2024 | 4471 | 0.100 |
Why?
|
Botswana | 5 | 2016 | 1048 | 0.100 |
Why?
|
Carotid Arteries | 2 | 2015 | 941 | 0.100 |
Why?
|
Jaundice | 1 | 2012 | 94 | 0.100 |
Why?
|
Genotype | 7 | 2012 | 12990 | 0.100 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11461 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 676 | 0.100 |
Why?
|
Young Adult | 17 | 2020 | 59255 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2177 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12059 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2016 | 771 | 0.100 |
Why?
|
Deoxycytidine | 2 | 2014 | 877 | 0.100 |
Why?
|
Survival Analysis | 2 | 2019 | 10090 | 0.090 |
Why?
|
Bilirubin | 1 | 2012 | 436 | 0.090 |
Why?
|
Central Nervous System Diseases | 2 | 2005 | 520 | 0.090 |
Why?
|
Health Resources | 2 | 2014 | 935 | 0.090 |
Why?
|
Prevalence | 4 | 2024 | 15732 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2014 | 662 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1589 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 235 | 0.090 |
Why?
|
Antiviral Agents | 2 | 2015 | 3060 | 0.090 |
Why?
|
Models, Biological | 2 | 2010 | 9469 | 0.090 |
Why?
|
Polymorphism, Genetic | 4 | 2013 | 4243 | 0.080 |
Why?
|
Patient Selection | 2 | 2020 | 4244 | 0.080 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 8002 | 0.080 |
Why?
|
Placebos | 3 | 2024 | 1667 | 0.080 |
Why?
|
Premature Birth | 2 | 2012 | 1782 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3384 | 0.080 |
Why?
|
Stillbirth | 1 | 2012 | 368 | 0.080 |
Why?
|
Cohort Studies | 11 | 2021 | 41493 | 0.080 |
Why?
|
HLA-B Antigens | 1 | 2010 | 317 | 0.080 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 26127 | 0.080 |
Why?
|
Aged | 19 | 2024 | 169310 | 0.080 |
Why?
|
Carotid Artery Diseases | 1 | 2015 | 877 | 0.080 |
Why?
|
Cytomegalovirus | 2 | 2024 | 756 | 0.080 |
Why?
|
Attitude to Health | 2 | 2016 | 2025 | 0.080 |
Why?
|
Comorbidity | 2 | 2020 | 10508 | 0.080 |
Why?
|
Genetic Variation | 3 | 2012 | 6567 | 0.080 |
Why?
|
Epistasis, Genetic | 1 | 2011 | 352 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 3416 | 0.080 |
Why?
|
Endothelium, Vascular | 1 | 2020 | 4431 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2016 | 1334 | 0.080 |
Why?
|
Prospective Studies | 13 | 2022 | 54426 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1964 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 1802 | 0.080 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2023 | 4369 | 0.070 |
Why?
|
Bone Density Conservation Agents | 1 | 2015 | 795 | 0.070 |
Why?
|
Antibodies, Viral | 3 | 2024 | 3156 | 0.070 |
Why?
|
Half-Life | 2 | 2005 | 651 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 832 | 0.070 |
Why?
|
Birth Weight | 2 | 2012 | 2103 | 0.070 |
Why?
|
Purine Nucleosides | 1 | 2006 | 30 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2243 | 0.070 |
Why?
|
Dioxolanes | 1 | 2006 | 23 | 0.070 |
Why?
|
Drug Administration Schedule | 5 | 2014 | 4853 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2011 | 560 | 0.060 |
Why?
|
HIV Fusion Inhibitors | 1 | 2006 | 82 | 0.060 |
Why?
|
Body Mass Index | 5 | 2023 | 12954 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2904 | 0.060 |
Why?
|
United States | 8 | 2023 | 72335 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2010 | 1251 | 0.060 |
Why?
|
Endpoint Determination | 2 | 2013 | 590 | 0.060 |
Why?
|
Calcium | 1 | 2017 | 5722 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2007 | 429 | 0.060 |
Why?
|
Adolescent | 10 | 2020 | 88324 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2016 | 39107 | 0.060 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2006 | 303 | 0.060 |
Why?
|
Time Factors | 9 | 2019 | 39970 | 0.050 |
Why?
|
Bone Resorption | 2 | 2019 | 723 | 0.050 |
Why?
|
Gestational Age | 1 | 2011 | 3577 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2019 | 1869 | 0.050 |
Why?
|
Thailand | 2 | 2014 | 287 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2013 | 3826 | 0.050 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2023 | 127 | 0.050 |
Why?
|
South Africa | 2 | 2021 | 1843 | 0.050 |
Why?
|
Sample Size | 1 | 2006 | 841 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2015 | 3415 | 0.050 |
Why?
|
Cholesterol, LDL | 2 | 2024 | 2382 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2023 | 3096 | 0.050 |
Why?
|
Genome-Wide Association Study | 4 | 2015 | 12690 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 23996 | 0.050 |
Why?
|
Drug Therapy | 2 | 2015 | 503 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2024 | 4544 | 0.050 |
Why?
|
Africa | 2 | 2015 | 709 | 0.050 |
Why?
|
Floxuridine | 1 | 2000 | 44 | 0.050 |
Why?
|
Research | 1 | 2010 | 1982 | 0.050 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2020 | 34 | 0.050 |
Why?
|
Patient Compliance | 3 | 2007 | 2690 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2010 | 2571 | 0.040 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6484 | 0.040 |
Why?
|
North America | 1 | 2024 | 1276 | 0.040 |
Why?
|
Mutation | 6 | 2021 | 30054 | 0.040 |
Why?
|
Infusion Pumps, Implantable | 1 | 2000 | 158 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2000 | 369 | 0.040 |
Why?
|
Adipose Tissue | 2 | 2023 | 3312 | 0.040 |
Why?
|
Integrases | 1 | 2022 | 518 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 2017 | 1803 | 0.040 |
Why?
|
Genetic Testing | 1 | 2012 | 3537 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 220 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1576 | 0.040 |
Why?
|
Proteomics | 2 | 2023 | 3848 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 12463 | 0.040 |
Why?
|
Mood Disorders | 1 | 2005 | 1127 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2012 | 5492 | 0.040 |
Why?
|
Pilot Projects | 4 | 2015 | 8633 | 0.040 |
Why?
|
Pregnancy | 7 | 2016 | 29876 | 0.040 |
Why?
|
Lipids | 3 | 2016 | 3341 | 0.040 |
Why?
|
Blood Proteins | 1 | 2023 | 1173 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2202 | 0.040 |
Why?
|
Blood Glucose | 3 | 2021 | 6391 | 0.030 |
Why?
|
Biological Availability | 1 | 2017 | 390 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2000 | 646 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15266 | 0.030 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2018 | 422 | 0.030 |
Why?
|
India | 2 | 2014 | 2348 | 0.030 |
Why?
|
Transsexualism | 1 | 2020 | 208 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1416 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2020 | 22176 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2005 | 2220 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2264 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2014 | 134 | 0.030 |
Why?
|
Drug Combinations | 2 | 2014 | 2048 | 0.030 |
Why?
|
Longitudinal Studies | 3 | 2015 | 14607 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2017 | 581 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5872 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1422 | 0.030 |
Why?
|
Asia | 1 | 2015 | 619 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10766 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5112 | 0.030 |
Why?
|
Developing Countries | 2 | 2016 | 2885 | 0.030 |
Why?
|
Malawi | 1 | 2014 | 304 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2015 | 270 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2013 | 361 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2014 | 413 | 0.030 |
Why?
|
Osteoprotegerin | 1 | 2013 | 176 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1203 | 0.030 |
Why?
|
Triglycerides | 1 | 2020 | 2461 | 0.030 |
Why?
|
Pyridazines | 1 | 2014 | 202 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2023 | 2639 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2016 | 754 | 0.020 |
Why?
|
Consensus | 1 | 2022 | 3123 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2022 | 2691 | 0.020 |
Why?
|
Birth Certificates | 1 | 2011 | 71 | 0.020 |
Why?
|
Infant, Newborn | 4 | 2013 | 26198 | 0.020 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2011 | 63 | 0.020 |
Why?
|
RANK Ligand | 1 | 2013 | 318 | 0.020 |
Why?
|
Meningioma | 1 | 2000 | 1218 | 0.020 |
Why?
|
Hypertension | 1 | 2011 | 8540 | 0.020 |
Why?
|
Metabolism, Inborn Errors | 1 | 2013 | 284 | 0.020 |
Why?
|
Meningeal Neoplasms | 1 | 2000 | 1248 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3725 | 0.020 |
Why?
|
Chemoprevention | 1 | 2013 | 326 | 0.020 |
Why?
|
Disease Progression | 3 | 2014 | 13510 | 0.020 |
Why?
|
Receptors, Drug | 1 | 2011 | 157 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6075 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 140 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2231 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 144 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3769 | 0.020 |
Why?
|
Biometry | 1 | 2013 | 563 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 325 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1039 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2015 | 4580 | 0.020 |
Why?
|
Tanzania | 1 | 2014 | 1387 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2015 | 1738 | 0.020 |
Why?
|
Nitriles | 1 | 2014 | 971 | 0.020 |
Why?
|
Spouses | 1 | 2011 | 283 | 0.020 |
Why?
|
Infant, Small for Gestational Age | 1 | 2011 | 461 | 0.020 |
Why?
|
Dreams | 1 | 2009 | 146 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3873 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2023 | 4948 | 0.020 |
Why?
|
Gene Dosage | 1 | 2012 | 1218 | 0.020 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2008 | 53 | 0.020 |
Why?
|
Breast Feeding | 1 | 2016 | 1360 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14666 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 563 | 0.020 |
Why?
|
Adiponectin | 1 | 2013 | 1113 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7396 | 0.020 |
Why?
|
Sex Factors | 2 | 2011 | 10553 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4077 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1440 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2022 | 10448 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5841 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2012 | 1722 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2013 | 1315 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5869 | 0.020 |
Why?
|
Antigens, CD | 1 | 2016 | 4001 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2010 | 617 | 0.020 |
Why?
|
Weight Gain | 1 | 2016 | 2348 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 1739 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1298 | 0.020 |
Why?
|
Leptin | 1 | 2013 | 1597 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2011 | 1303 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2000 | 4319 | 0.020 |
Why?
|
Sulfonamides | 1 | 2014 | 1978 | 0.010 |
Why?
|
Stavudine | 1 | 2004 | 85 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2850 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2713 | 0.010 |
Why?
|
Diet | 1 | 2022 | 8075 | 0.010 |
Why?
|
Counseling | 1 | 2012 | 1547 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18398 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3208 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 5315 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2735 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8656 | 0.010 |
Why?
|
Gene Frequency | 1 | 2010 | 3606 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 3968 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15843 | 0.010 |
Why?
|
Brain | 1 | 2009 | 27120 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2004 | 412 | 0.010 |
Why?
|
Pyrimidines | 1 | 2014 | 3028 | 0.010 |
Why?
|
Lactic Acid | 1 | 2007 | 1139 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2472 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5311 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2000 | 6935 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5439 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 14032 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1638 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5972 | 0.010 |
Why?
|
Genome, Human | 1 | 2012 | 4425 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6864 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9610 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2000 | 9031 | 0.010 |
Why?
|
Computational Biology | 1 | 2011 | 3517 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 3066 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2012 | 80646 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21355 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6344 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2002 | 13382 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7391 | 0.010 |
Why?
|
Software | 1 | 2011 | 4434 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2009 | 7054 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 5035 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13255 | 0.010 |
Why?
|
Anxiety | 1 | 2009 | 4573 | 0.010 |
Why?
|
Neoplasms | 2 | 2014 | 22173 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7529 | 0.010 |
Why?
|
Infant | 1 | 2016 | 36192 | 0.010 |
Why?
|
Child | 1 | 2022 | 80156 | 0.010 |
Why?
|
Child, Preschool | 1 | 2016 | 42230 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2007 | 3963 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36429 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2012 | 58986 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2006 | 12794 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12148 | 0.010 |
Why?
|
Depression | 1 | 2009 | 8124 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2000 | 8528 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16592 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2000 | 20099 | 0.000 |
Why?
|